Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study.
Barbara RuaroAndrea SalottiNicolò ReccardiniStefano KetteBeatrice Da ReSalvatore NicolosiUmberto ZucconMarco ConfalonieriLucrezia MondiniRiccardo PozzanMichael HughesPaola ConfalonieriFrancesco SaltonPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
This study highlights the functional decline of the FVC at 12 months after the NTD initiation among patients discontinuing therapy but not among those reducing their dosage.